Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment
Findings Presented at ATS 2022
“Our analysis showed that the nasal genomic classifier performed similarly well in patients across the spectrum of tobacco-related risk," said
For the study, researchers evaluated data from a subset of 291 current and former smokers with lung nodules who were part of the original clinical validation study for the Percepta Nasal Swab test. Among these individuals, 213 (73%) met USPSTF screening criteria (pack years ≥20, years since quit <15, age 50-80 years), while 78 (27%) did not. Researchers compared the performance of the classifier in the two patient subsets and found no statistically significant differences in the classifier’s sensitivity and specificity between the two groups.
Specifically, among those who met the USPSTF criteria for lung cancer screening, the test’s sensitivity was 96% when it identified a nodule as low risk for cancer and its specificity was 94% when it identified it as high risk. Among patients who did not meet the USPSTF lung cancer screening eligibility, the test’s sensitivity was 100% when it identified nodules as low risk for cancer and its specificity was 88% when it identified them as high risk.
“The data presented today reinforce the important role that the Percepta Nasal Swab classifier may play in helping to guide next steps for current and former smokers with lung nodules – including those who may be considered low risk based on their smoking history burden,” said
The Percepta Nasal Swab test’s performance in classifying lung cancer risk has previously been demonstrated, and it is being made available to a limited number of sites as the company develops the clinical utility evidence to support reimbursement.
Also at ATS 2022,
Title: Integrating novel genomic data to improve ILD diagnostic and prognostic confidence
Title: Integrating the Percepta Genomic Sequencing Classifier for lung nodule risk stratification
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to Veracyte’s Percepta Nasal Swab test. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," “suggest,” "may," "will" “prospective” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. An example of a forward-looking statement includes, among others, that the Percepta Nasal Swab may help patients more accurately, quickly and confidently assess lung cancer risk so that patients may avoid unnecessary invasive procedures. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220516006017/en/
Vice President of